Informazioni sul prodotto
- Cgp 45715A
- (S-(R*,S*-(E,Z)))-7-((9-(4-Acetyl-3-hydroxy-2-propylphenoxy)-1-(hydroxy(3-(trifluoromethyl)phenyl)methyl)-2,4-nonadienyl)thio)-4-oxo-4H-1-benzopyran-2-carboxylic acid monosodium salt
- 1-Hydroxy-1-(3-trifluoromethylphenyl)-10-(4-acetyl-3-hydroxy-2-propylphenoxy)deca-3(E),5(Z)-diene-2-yl-7-thio-4-oxo-4H-1-benzopyran-2-carboxylic acid
- Cgp-45715 A
- 4H-1-Benzopyran-2-carboxylic acid, 7-((9-(4-acetyl-3-hydroxy-2-propylphenoxy)-1-(hydroxy(3-(trifluoromethyl)phenyl)methyl)-2,4-nonadienyl)thio)-4-oxo-, monosodium salt, (S-(R*,S*-(E,Z)))-
- sodium 7-{[(1S,2E,4Z)-9-(4-acetyl-3-hydroxy-2-propylphenoxy)-1-{(R)-hydroxy[3-(trifluoromethyl)phenyl]methyl}nona-2,4-dien-1-yl]sulfanyl}-4-oxo-4H-chromene-2-carboxylate
Iralukast Na is a leukotriene receptor antagonist that prevents bronchoconstrictor response. It binds to the cystic fibrosis transmembrane conductance regulator (CFTR) and blocks the binding of leukotrienes, which are potent bronchoconstrictors. Iralukast Na also blocks the activity of inflammatory cells and reduces bowel inflammation. Iralukast Na has been shown to be effective in treating asthma, inflammatory bowel disease, and other autoimmune diseases.
Proprietà chimiche
Richiesta tecnica su: 3D-FS104155 Iralukast Na
Se si desidera richiedere un preventivo o effettuare un ordine, si prega invece di aggiungere i prodotti desiderati al carrello e poi richiedere un preventivo o un ordine dal carrello. È più veloce, più economico, e potrà beneficiare degli sconti disponibili e di altri vantaggi.